Core Viewpoint - Freeport-McMoran Inc. is facing a class action lawsuit due to alleged securities fraud related to safety issues at its Grasberg Block Cave operation in Indonesia, which resulted in significant stock price declines following a tragic incident involving trapped workers [2][3][4][5][6]. Incident Overview - On September 9, 2025, Freeport announced the suspension of mining activities at the Grasberg Block Cave after a large flow of wet material trapped seven workers, leading to a stock price drop of $2.77, or 5.9%, closing at $43.89 per share [2]. - An update on September 24, 2025, revealed that two of the trapped workers had died, causing the stock price to fall by $7.69, or 17%, to close at $37.67 per share [3]. - Following media reports on September 25, 2025, regarding the implications of the production halt on Freeport's relationship with the Indonesian government, the stock price dropped another $2.33, or 6.2%, closing at $35.34 [4]. Lawsuit Details - The class action lawsuit alleges that Freeport made materially false and misleading statements and failed to disclose critical safety risks associated with its operations [5][6]. - Specific allegations include inadequate safety measures at the Grasberg mine, which heightened the risk of worker fatalities and led to undisclosed regulatory and reputational risks [6].

Nov 21, 2025 1:26 PM Eastern Standard Time Deadline Approaching: Perrigo Company plc (PRGO) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith Share BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming January 16, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Perrigo Company plc ("Perrigo†or the "Company†) (NYSE: PRGO) securities between February 27, 2023 and November 4, 2025, inclus ...

Core Viewpoint - Fortinet, Inc. is facing a securities fraud class action lawsuit due to misleading statements regarding its business operations and financial performance, particularly related to its firewall upgrade cycle and revenue guidance [4][2]. Group 1: Lawsuit Details - The lawsuit is based on allegations that Fortinet made materially false and misleading statements during the class period from November 8, 2024, to August 6, 2025 [4][5]. - The company reported that it was only "approximately 40% to 50% of the way through the 2026 firewall upgrade cycle" by the end of Q2 2025, which contradicted earlier expectations [2][4]. - Following the release of disappointing financial results and guidance, Fortinet's stock price dropped by $21.28, or 22%, closing at $75.30 per share on August 7, 2025 [3][2]. Group 2: Financial Performance - Fortinet's revenue guidance for Q3 2025 was projected between $1.67 billion and $1.73 billion, which was weaker than market expectations [2]. - The lawsuit claims that the refresh cycle for Fortinet's products was not as lucrative as represented, and the company misrepresented the number of firewalls eligible for upgrades [4]. Group 3: Investor Actions - Investors who acquired Fortinet common stock during the class period are urged to participate in the lawsuit, with a deadline set for November 21, 2025, to seek lead plaintiff status [5][4].

Core Viewpoint - The Law Offices of Howard G. Smith is urging investors of Primo Brands Corporation (PRMB) who suffered losses to participate in a class action lawsuit due to alleged securities fraud related to the company's merger and subsequent operational issues [1][5]. Summary by Sections Company Background - Primo Brands Corporation operates under the NYSE ticker PRMB and was formed following a merger between Primo Water Corporation and BlueTriton Brands, Inc. on November 8, 2024 [3]. Financial Performance and Stock Impact - On August 7, 2025, Primo Brands reported second quarter 2025 financial results, revealing that rapid facility closures and headcount reductions disrupted product supply and delivery, leading to a stock price drop of $2.41, or 9.1%, closing at $24.00 per share [3]. - Following the announcement on November 6, 2025, regarding the replacement of its CEO and a reduction in full-year 2025 net sales and adjusted EBITDA guidance, the stock price fell by $8.20, or 36.2%, closing at $14.46 per share on November 7, 2025 [4]. Lawsuit Details - The class action lawsuit alleges that during the class period, the defendants made materially false and misleading statements and failed to disclose significant operational issues, including poor merger integration and major supply disruptions that negatively impacted financial results [5][6]. - Investors who purchased Primo Brands common stock during the specified class period (November 11, 2024, to November 6, 2025) are encouraged to file a lead plaintiff motion by January 12, 2026, if they meet legal requirements [1][6].

Core Viewpoint - Aurora Cannabis Inc. reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, and showing a significant increase from $0.04 per share a year ago, representing an earnings surprise of +200.00% [1][2] Financial Performance - The company posted revenues of $65.62 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 2.88%, and an increase from $59.47 million in the same quarter last year [2] - Over the last four quarters, Aurora Cannabis has exceeded consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Performance and Outlook - Aurora Cannabis shares have increased by approximately 6.8% since the beginning of the year, while the S&P 500 has gained 15.1% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the sustainability of the recent earnings numbers [3][4] Earnings Estimates and Revisions - The current consensus EPS estimate for the upcoming quarter is $0.28 on revenues of $69 million, while for the current fiscal year, the estimate is -$0.31 on revenues of $271.75 million [7] - Prior to the earnings release, the trend for estimate revisions was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting that the industry outlook may negatively impact stock performance [8]

Core Viewpoint - Bio-Rad Laboratories reported quarterly earnings of $2.26 per share, missing the Zacks Consensus Estimate of $2.3 per share, but showing an increase from $2.01 per share a year ago [1][2]. Financial Performance - The company posted revenues of $653 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 0.24% and showing a slight increase from $649.73 million year-over-year [3]. - The earnings surprise for the quarter was -1.74%, while the previous quarter saw a positive surprise of +35.23% with actual earnings of $2.61 compared to an expected $1.93 [2]. Market Performance - Bio-Rad shares have increased by approximately 0.6% since the beginning of the year, in contrast to the S&P 500's gain of 17.2% [4]. - The current Zacks Rank for Bio-Rad is 4 (Sell), indicating expectations of underperformance in the near future [7]. Future Outlook - The consensus EPS estimate for the upcoming quarter is $2.57 on revenues of $693.11 million, and for the current fiscal year, it is $10.02 on revenues of $2.58 billion [8]. - The Medical - Products industry, to which Bio-Rad belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [9].

Group 1 - Cresco Labs Inc. reported a quarterly loss of $0.05 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.04, and improved from a loss of $0.16 per share a year ago, indicating a surprise of -25.00% [1] - The company posted revenues of $163.62 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 0.15%, and down from $184.36 million in the same quarter last year [2] - Cresco Labs Inc. shares have declined approximately 24.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.9% [3] Group 2 - The earnings outlook for Cresco Labs Inc. is uncertain, with current consensus EPS estimates at -$0.03 on revenues of $169.47 million for the upcoming quarter and -$0.11 on revenues of $675.98 million for the current fiscal year [7] - The Zacks Industry Rank places the Medical - Products sector in the bottom 37% of over 250 Zacks industries, suggesting that the industry outlook could significantly impact stock performance [8] Group 3 - The estimate revisions trend for Cresco Labs Inc. was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Insulet (PODD) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $0.81 per share. This compares to earnings of $0.73 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 25.93%. A quarter ago, it was expected that this maker of insulin infusion systems would post earnings of $1.05 per share when it actually produced earnings of $1.15, delivering a surprise of 9.52%.Over the last four quart ...

Core Viewpoint - Sanara MedTech Inc. is set to present at the Planet MicroCap Showcase: VEGAS 2025, highlighting its focus on developing transformative medical technologies aimed at improving clinical outcomes and reducing healthcare costs in surgical, chronic wound, and skincare markets [1] Company Overview - Sanara MedTech Inc. specializes in medical technology, focusing on the development and commercialization of innovative products to enhance clinical outcomes and lower healthcare expenditures [3] - The company markets and distributes a range of surgical, wound, and skincare products primarily in the North American advanced wound care and surgical tissue repair markets [3] - Key products include CellerateRX® Surgical Activated Collagen®, FORTIFY TRG® Tissue Repair Graft, and various advanced biologic products such as ACTIGEN® Verified Inductive Bone Matrix and BIASURGE® Advanced Surgical Solution [3] - Sanara also offers telemedicine services for wound care and dermatology consultations, aiming to improve patient outcomes while managing costs [3] Upcoming Presentation - Management will present to investors on April 23, 2025, at approximately 3:30 p.m. Pacific Time during the Planet MicroCap Showcase [1] - Presentation materials will be available on the company's investor relations website prior to the event, along with a live audio webcast and an archive for later access [2]

Company Overview - Sanara MedTech Inc. (SMTI) shares increased by 8.1% to $29.20 in the last trading session, following a significant volume of trading, contrasting with a 15.5% loss over the past four weeks [1] - The recent stock price increase is attributed to a relief rally in global markets due to a 90-day pause on tariff hikes announced by the United States [1] Earnings Expectations - Sanara MedTech is projected to report a quarterly loss of $0.31 per share, reflecting a year-over-year decline of 47.6% [2] - Expected revenues for the upcoming quarter are $22.25 million, which represents a 20% increase compared to the same quarter last year [2] Earnings Estimate Revisions - The consensus EPS estimate for Sanara MedTech has been revised down by 16% over the last 30 days [3] - A negative trend in earnings estimate revisions typically does not lead to price appreciation, indicating potential caution for future stock performance [3] Industry Context - Sanara MedTech operates within the Zacks Medical - Products industry, where another company, Perrigo (PRGO), saw its shares rise by 5.4% to $25.87, despite a -11.9% return over the past month [3] - Perrigo's consensus EPS estimate has decreased by 9.2% over the past month to $0.53, which is an increase of 82.8% compared to the previous year [4]